Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADU-1604 in Metastatic Melanoma
NCT03674502Phase 1Terminated
- Sponsor
- Aduro Biotech, Inc.
- Start
- Nov 2018
- Primary completion
- Aug 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ADU-1604 in melanoma, sponsored by Aduro Biotech, Inc. Primary endpoint: Recommended Phase 2 Dose at 9 months. Started Nov 2018; status: terminated.
02
Drugs
ADU-1604
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03674502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03674502.